Metformin, a first‐line drug prescribed for type 2 diabetes and a well‐established AMPK activator, has been proven to exert beneficial effects on stroke patients and to increase hippocampal neurogenesis in preclinical studies via the atypical protein kinase C (aPKC)‐CREB‐binding protein (CBP) pathway 43, 44, 45. This evidence concerns the gene PRKAA2 and stroke disorder.